drugset / Trial / NCT06586671

A Study to Compare Forms of Nemtabrutinib (MK-1026) in Healthy Adult Participants (MK-1026-007)

NCT06586671

Phase 1 Completed 40 enrolled Merck Sharp & Dohme LLC
RandomizedCrossoverOpen-labelBasic science

Summary

The goal of the study is to measure and compare the levels of nemtabrutinib in the blood after taking different forms of nemtabrutinib orally on an empty stomach (fasted) to see if they are the same or different.

Timeline

Start
2023-08-28
Primary completion
2023-11-13
Completion
2023-11-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Nemtabrutinib Other / unclassified 65 mg Oral